Orakl Oncology raises $34M Series A to predict cancer drug results with AI
This story is from 2026-11-12. It is preserved in the archive; the latest stories are on the live feed.
Paris-based Orakl Oncology raised a $34M Series A co-led by Norrsken VC and Singular. The startup grows copies of patients' tumours in the lab, tests drugs on them and uses AI to predict trial results.
Read the full story at The Next Web ↗
Timeline · 1 report
- 2026-11-12 17:31 · The Next Web
Orakl Oncology raises $34M to predict cancer drug results with AI